Exebio Luis E Moreno, Rodríguez Javier, Sayritupac Freddy
Centro Nacional de Control de Calidad, Instituto Nacional de Salud, Perú.
Rev Panam Salud Publica. 2010 Feb;27(2):138-43. doi: 10.1590/s1020-49892010000200008.
To determine the quantity of counterfeit pharmaceutical drugs found by the National Quality Control Center (Centro Nacional de Control de Calidad (CNCC), Instituto Nacional de Salud, Peru) during the period from 2005&2008, and the types and properties of these drugs.
A form was created to amass the relevant data collected directly from CNCC reports. The reports underwent a review and analysis process, and where counterfeiting was confirmed, it was categorized by type into one of four groups.
The percentage of counterfeit drugs relative to the total drugs evaluated was: 3.0% in 2005, 5.0% in 2006, 7.3% in 2007, and 9.2% in 2008. The main groups of counterfeit drugs, classified according to the World Health Organization Anatomical Therapeutic Chemical Classification System, were: alimentary tract and metabolism, 34.5% (29.1%-39.8%); antiinfectives for systemic use, 21.1% (16.5%-25.7%); nervous system, 17.1% (12.8%-21.3%); and musculo-skeletal system, 15.4% (11.3%-19.5%). The most common type of forgery occurred in cases where the drug contained the correct amount of active ingredients, but the manufacturer was one other than the one indicated (62.4% of the total counterfeit drugs); and medications that did not contain any active ingredient (22.4%). Of the counterfeit drugs, 61.0% (56.0%-67.0%) were national brands and 39.0%, (33.0%-44.0%) were imported. The pharmaceutical formulations with the highest rate of forgery were tablets, 66.0% (60.0%-71.0%); injectables, 19.0% (14.0%-23.0%); and capsules 7.0% (4.0%-10.0%).
From 2005-2008, drug counterfeiting had an average annual variation of 45%. Drug counterfeiting was shown to be most prevalent among national brands - as opposed to imported medications - although the types and formulations of the fake drugs attest to a certain level of sophistication employed in the forgery process. The counterfeiting of life-saving drugs, such as antimicrobials, signifies a serious public health threat.
确定秘鲁国家卫生研究院国家质量控制中心(Centro Nacional de Control de Calidad,CNCC)在2005年至2008年期间查获的假药数量以及这些假药的类型和性质。
设计了一份表格,用于汇总直接从CNCC报告中收集的相关数据。对这些报告进行了审查和分析,对于确认存在假冒情况的,按类型分为四组之一。
假药占评估药品总数的百分比分别为:2005年3.0%,2006年5.0%,2007年7.3%,2008年9.2%。根据世界卫生组织解剖治疗学化学分类系统分类,假药的主要类别为:消化道及代谢类,34.5%(29.1%-39.8%);全身用抗感染药,21.1%(16.5%-25.7%);神经系统类,17.1%(12.8%-21.3%);肌肉骨骼系统类,15.4%(11.3%-19.5%)。最常见的伪造类型是药品所含活性成分数量正确,但制造商并非标明的制造商(占假药总数的62.4%),以及不含任何活性成分的药品(22.4%)。在假药中,61.0%(56.0%-67.0%)是国产品牌,39.0%(33.0%-44.0%)是进口品牌。伪造率最高的药物剂型是片剂,66.0%(60.0%-71.0%);注射剂,19.0%(14.0%-23.0%);胶囊剂,7.0%(4.0%-10.0%)。
2005年至2008年期间,假药情况的年平均变化率为45%。假药在国产品牌中最为普遍,与进口药品不同,尽管假药的类型和剂型表明造假过程具有一定的复杂性。抗菌药物等救命药品的造假对公众健康构成严重威胁。